Cagrilintide: Dosage, Protocol, and Research Guide
Long-acting amylin receptor agonist being developed in combination with semaglutide
Mechanism
Synthetic analog of amylin that slows gastric emptying, suppresses glucagon secretion, and promotes satiety through different pathways than GLP-1. Complementary mechanism when combined with GLP-1 agonists.
Protocol at a glance
| Starting dose | 0.3mg |
|---|---|
| Maintenance dose | 1.2-2.4mg |
| Maximum dose | 2.4mg |
| Frequency | Once daily |
| Typical duration | Ongoing therapy |
| Route | Subcutaneous |
| Injection site | Abdomen or thigh |
| Timing | Any time of day |
Side effects
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
Contraindications
- Gastroparesis
- Hypoglycemia unawareness
Protocol notes
- Often combined with semaglutide (CagriSema)
- Targets different pathway than GLP-1
- Enhances satiety through amylin receptors
- Currently in clinical development
Frequently asked questions
What is Cagrilintide and how does it work?
Cagrilintide is a long-acting amylin receptor agonist, a synthetic analog of the natural hormone amylin, currently in clinical development for weight management. It works through three complementary mechanisms: it slows gastric emptying to extend satiety signals, suppresses glucagon secretion to support glucose regulation, and directly activates amylin receptors to promote appetite suppression. These multiple pathways make Cagrilintide particularly effective when combined with GLP-1 agonists like semaglutide.
Is Cagrilintide FDA-approved for human use?
No. Cagrilintide is not currently FDA-approved for human use. It remains in clinical development, meaning it is available only through authorized clinical trials, research institutions, or in jurisdictions where it has received regulatory approval. Any use of Cagrilintide must occur under the direct medical supervision of a qualified healthcare provider. For research purposes only — not FDA-approved for human use.
What is the dosing protocol for Cagrilintide?
Cagrilintide follows a titration protocol beginning with a starting dose of 0.3mg daily. Maintenance doses range from 1.2mg to 2.4mg daily, with a maximum dose of 2.4mg. The peptide is administered as a once-daily subcutaneous injection. Dosing can be flexible in terms of timing—injections can be given at any time of day. Cagrilintide is designed for ongoing therapy rather than short-term treatment.
Can Cagrilintide be combined with semaglutide?
Yes. Cagrilintide is frequently used in combination with semaglutide, a combination formulation known as CagriSema. The two agents target different receptor systems—Cagrilintide targets amylin receptors while semaglutide targets GLP-1 receptors—creating complementary mechanisms of action. When combined, they produce synergistic effects on appetite suppression and satiety, potentially delivering superior weight loss outcomes compared to either agent used alone.
What are the side effects of Cagrilintide?
Common side effects of Cagrilintide include nausea, vomiting, decreased appetite, and injection site reactions. These effects are typically dose-dependent and often diminish as the body adapts to treatment over time. The most frequently experienced side effect is nausea, which tends to be manageable and temporary for most users. If side effects persist or become problematic, dosing adjustments may be considered under medical supervision.
Who should not use Cagrilintide?
Cagrilintide is contraindicated in specific populations. Individuals with gastroparesis (delayed gastric emptying) should not use Cagrilintide, as its mechanism of slowing gastric emptying could worsen this condition. Additionally, people with hypoglycemia unawareness should avoid Cagrilintide, as its glucagon-suppressing effects could pose safety risks. Anyone considering Cagrilintide should discuss their full medical history with a qualified healthcare provider.
How is Cagrilintide administered?
Cagrilintide is administered as a subcutaneous injection once daily. Injections can be given into either the abdomen or the thigh. A key advantage of Cagrilintide is timing flexibility—patients can inject at any time of day that fits their routine, without strict time-of-day requirements. The injection process is similar to other subcutaneous peptides and can be self-administered once a patient has received proper training.
How does Cagrilintide differ from GLP-1 agonists?
Cagrilintide and GLP-1 agonists work through fundamentally different mechanisms. GLP-1 agonists target GLP-1 receptors, while Cagrilintide targets amylin receptors. This distinction means they suppress appetite and regulate satiety through different biological pathways. Because of these complementary mechanisms, Cagrilintide and GLP-1 agonists like semaglutide are often combined rather than used as alternatives, allowing clinicians to leverage multiple pathways for enhanced weight management outcomes.
More GLP-1 & Weight Loss peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.